drugset / Trial / NCT00034359
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
Phase 2
Completed
79 enrolled
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study was to determine the safety and anti-hepatitis B virus (-HBV) activity of ACH-126,443 in comparison to lamivudine or placebo in treatment-naive adults with chronic hepatitis B infection.
Timeline
- Start
- 2002-02
- Primary completion
- 2003-01
- Completion
- 2003-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elvucitabine | Small molecule | — | Oral |
| Subject | Lamivudine | Other / unclassified | — | — |